De Backer Marianne 4

What Happened
Marianne De Backer, President, CEO and Director of Vir Biotechnology, reported a non‑market transfer of 233,532 shares on 2026-04-29. The Form 4 shows both a disposition and an acquisition of 233,532 shares at $0.00—meaning the shares were moved without cash consideration. The filing lists the transaction value as $0.00.

Key Details

• Transaction date: 2026-04-29; Filed: 2026-04-30 (appears timely).
• Reported price: $0.00 for both the disposition and acquisition entries (transaction code J: "Other acquisition or disposition").
• Shares transferred: 233,532 shares (disposed and acquired — effectively a transfer).
• Shares owned after transaction: Not specified in the provided filing (the Form 4 shows the transfer amount but not total post‑transaction beneficial ownership here).
• Footnotes: F1 indicates this was a "transfer without consideration for tax and estate planning purposes." F2 states the shares are held in the name of the Ureel‑De Backer Family Trust, of which the Reporting Person and her spouse are Trustees.

Context
Transfers to or from a family trust are commonly done for estate or tax planning and are not market purchases or sales; they do not necessarily indicate the insider’s view of the company’s prospects. The $0.00 entries and the footnotes confirm this was an internal transfer rather than a sale or open‑market purchase.